Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Race Oncology Ltd. ( (AU:RAC) ) has issued an update.
Racura Oncology Ltd has applied for quotation on the ASX of 5,469 new ordinary fully paid shares following the exercise or conversion of existing options or other convertible securities, with an issue date of 2 January 2026. The modest increase in quoted securities slightly expands the company’s share capital base and reflects ongoing capital management activity, but does not, on the information provided, indicate a material change to its operations or strategic position.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australian-listed biotechnology company focused on oncology, with its ordinary fully paid shares traded on the ASX under the code RAC. The company operates in the cancer therapeutics sector, though this filing provides only corporate and capital markets details rather than product or clinical information.
Average Trading Volume: 409,193
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$486.4M
See more insights into RAC stock on TipRanks’ Stock Analysis page.